申请人:FISCHER Peter Martin
公开号:US20090325983A1
公开(公告)日:2009-12-31
The present invention relates to compounds of formula 1
or pharmaceutically acceptable salts thereof, wherein
one of R
1
and R
2
is methyl, ethyl or isopropyl, and the other is H;
R
3
and R
4
are each independently H, branched or unbranched C
1
-C
6
alkyl, or aryl, and
wherein at least one of R
3
and R
4
is other than H;
R
5
is a branched or unbranched C
1
-C
5
alkyl group or a C
1
-C
6
cycloalkyl group, each of which may be optionally substituted with one or more OH groups;
R
6
, R
7
, R
8
and R
9
are each independently H, halogen, NO
2
, OH, OMe, CN, NH
2
, COOH, CONH
2
, or SO
2
NH
2
.
A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.
本发明涉及公式1的化合物或其药学上可接受的盐,其中R1和R2中的一个是甲基、乙基或异丙基,另一个是氢;R3和R4各自独立地是氢、支链或非支链的C1-C6烷基或芳基,且其中至少一个不是氢;R5是支链或非支链的C1-C5烷基或C1-C6环烷基,每个基团都可以选择地用一个或多个OH基团进行取代;R6、R7、R8和R9各自独立地是氢、卤素、NO2、OH、OMe、CN、NH2、COOH、CONH2或SO2NH2。本发明的另一个方面涉及包含上述公式1化合物的制药组合物,以及在治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病中使用上述化合物的用途。